Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Sprint Bioscience Q3 - Steady sales and continued progress

Sprint Bioscience

Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.8m, mostly related to the Day One Biopharmaceuticals partner and the VADA project. The cash balance was SEK 31.7m in Q3 (36m in Q2 2024). Sprint Bioscience continues to market and attracts interest from potential partners for TREX1 (DISA), NNMT and STK25 programs, and during the quarter, Sprint Bioscience also completed the handover process for PETRA01. Our Base Case ahead is SEK 3.00 (Bull SEK 12 and Bear SEK 0.50).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Sprint Bioscience Q3 - Steady sales and continued progress

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.